Coherus Oncology Inc. (CHRS)
NASDAQ: CHRSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CHRS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $57.15M
- EPS (TTM)
- -$1.12
- Dividend yield
- None
- 52-week range
- 0.3628 – 2.62
- Day range
- 0.3628 – 0.4084
- Volume / Avg
- 2.52M / 1.80M
- Beta
- —
- Shares outstanding
- 154.54M
52-week range
CHRS stock today
Shares of Coherus Oncology (CHRS) finished lower on Nov 20 at $0.3698, a drop of 4.47% or $0.0173 per share, versus the S&P 500's 3.70% decline. At this level, CHRS sits near the bottom of its 52-week range of $0.3628 to $2.62: 85.9% below the high, set on Jan 27, 2026 and 1.9% above the low. CHRS is down 74.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 68.1%.
Coherus Oncology has posted a net loss over the last twelve months (EPS of -$1.12), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Coherus Oncology
Company profileCoherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Dennis M. Lanfear
- Headquarters
- Redwood City, CA
- Employees
- 144
- IPO year
- 2014
- Website
- coherus.com
Financial highlights
Full financialsIn fiscal 2025, Coherus Oncology generated $42.2 million in revenue, up 59.8% from fiscal 2024. Net income was $168.0 million (+489.4% year over year), for a net margin of 398.4% versus a median of -87.9% in the prior 5 years. Gross margin was 67.2% (up from 66.9%) and operating margin -429.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $42.17M | $26.39M | $257.24M | $211.04M | $326.55M |
| Growth | +59.81% | -89.74% | +21.89% | -35.37% | -31.37% |
| Net income | $168.02M | $28.51M | $-237.89M | $-291.75M | $-287.10M |
| EPS (diluted) | $1.43 | $0.25 | $-2.53 | $-3.76 | $-3.81 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$7.75+1995.73%
- Strong buy 1
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.38 vs $-0.22
- Surprise
- -72.73%
CHRS news
All CHRS news- Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike DealsNasdaqAMGN, ARGX, AZN, BEAM
- Oncolytics Partners With Coherus For Testing Pelareorep+LOQTORZI Combination In Anal CarcinomaNasdaqCHRS, ONCY, ET
- Coherus Oncology: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Coherus Oncology (CHRS) Q3 2026 Earnings Call TranscriptNasdaq
- Coherus Oncology, Inc. Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization PlanNasdaq
- Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization PlanGlobeNewswire
- Coherus Oncology, Inc. Reports 75% Confirmed ORR in First-Line ESCC Patients from Tagmokitug Interim Clinical DataNasdaq
- Coherus to Participate in Upcoming Investor ConferencesGlobeNewswire
Coherus Oncology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OKYOOKYO Pharma Limited | 1.07 | -7.76% | $56.15M | vs CHRS |
| CGTXCognition Therapeutics Inc. | 0.5822 | -3.06% | $55.37M | vs CHRS |
| AVXLAnavex Life Sciences Corp. | 0.5915 | -11.39% | $54.83M | vs CHRS |
| CSBRChampions Oncology Inc. | 4.34 | -1.36% | $60.41M | vs CHRS |
| NMRANeumora Therapeutics Inc. | 0.3339 | -3.78% | $63.01M | vs CHRS |
| ATRAAtara Biotherapeutics Inc. | 6.33 | -0.16% | $64.49M | vs CHRS |
| TNYATenaya Therapeutics Inc. | 0.2866 | -3.99% | $65.32M | vs CHRS |
| IMAImageneBio Inc. | 3.92 | 0.00% | $48.83M | vs CHRS |
Indexes, lists and sector
Coherus Oncology stock FAQ
What is Coherus Oncology's stock price today?
CHRS last traded at $0.3698 as of Nov 20, 4:00 PM EST, down 4.47% on the day. Prices are delayed at least 15 minutes.
Who is Coherus Oncology's CEO?
Mr. Dennis M. Lanfear is the chief executive officer of Coherus Oncology Inc., which has about 144 employees.
What is the CHRS 52-week high?
The 52-week high for CHRS is $2.62 and the 52-week low is $0.3628. The stock is currently 85.9% below its high.